| Identification | Back Directory | [Name]
GLPG-0778 | [CAS]
1206163-45-2 | [Synonyms]
CS-2178
G 154578
GLPG-0778
Solcitinib
GSK 2586184
GSK 2586184A
GLPG 0778;GLPG-0778
GLPG0778, GSK2586184
Solcitinib（GLPG0778）
Solcitinib (GSK2586184)
Solcitinib(GLPG0778,GSK2586184)
Solcitinib - GSK 2586184 | GLPG 0778
GLPG 0778;GSK 2586184;GLPG-0778;GSK-2586184
N-(5-(4-(3,3-Dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
Cyclopropanecarboxamide, N-[5-[4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]- | [Molecular Formula]
C22H23N5O2 | [MDL Number]
MFCD26960569 | [MOL File]
1206163-45-2.mol | [Molecular Weight]
389.45 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 2 mg/ml; DMSO: 5 mg/ml; Ethanol: 1 mg/ml | [form ]
A crystalline solid | [pka]
7.99±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Solcitinib is a JAK1 inhibitor (IC50 = 9.8 nM). It is greater than 10-fold selective for JAK1 over JAK2, JAK3, and TYK2. | [Uses]
Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis. | [IC 50]
JAK1: 9.8 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Ludbrook VJ, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95. DOI:10.1111/bjd.14399 |
|
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|